Table 4.
Clinical data for treatment of LAUPC using X-ray therapy plus chemotherapy, excluding the trials with gemcitabine.
| Reference | Year | Total dose (Gy) | Fractions | Chemotherapy | Sample size | 1 year OS | 2 years OS | Median OS (months) |
|---|---|---|---|---|---|---|---|---|
| Moertel et al. (39) | 1981 | 40 | 20 | 5-FU 500 mg/m2 3 days/week during RT, maintenance 5-FU 500 mg/m2 weekly | 83 | 46% | N/A | 11.4 |
| 60 | 30 | 85 | 35% | N/A | 8.4 | |||
| Wagener et al. (61) | 1996 | 40 | 20 | Epirubicin + Cisplatin + 5-FU | 53 | 49% | N/A | 10.8 |
| Ishii et al. (62) | 1997 | 50.4 | 28 | 5-FU 500 mg/m2 3 days/week during RT | 20 | 41.8% | N/A | 10.3 |
| Fisher et al. (63) | 1999 | 45 | 25 | 5-FU 150–250 mg/m2 continuous infusion 24 h/day during RT | 25 | 32% | N/A | 9 |
| Andre et al. (64) | 2000 | 45 | 25 | 5-FU 375 mg/m2 + Cisplatin 15 mg/m2 daily during RT (first and last week) + maintenance after RT | 32 | 31% | 12.5% | 9 |
| Boz et al. (65) | 2001 | 59.4 | 33 | 5-FU 150–300 mg/m2 continuous infusion 24 h/day during RT | 42 | 30% | N/A | 9.1 |
| Safran et al. (66) | 2001 | 50.4 | 28 | Paclitaxel 50 mg/m2 weekly during RT | 44 | 30% | N/A | 8 |
| Li et al. (67) | 2003 | 50.4–61.2 | 28–34 | 5-FU 500 mg/m2 for 3 days every 2 weeks during RT, Gem 1000 mg/m2 after RT | 16 | 31% | 0% | 6.7 |
| Morganti et al. (68) | 2004 | 39.6–59.4 | 22–33 | 5-FU 1000 mg/m2 during RT at days 1–4 and 21–24 | 50 | 31.3% | N/A | N/A |
| Cohen et al. (41) | 2005 | 59.4 | 33 | 5-FU 1000 mg/m2 at days 1–4 and 21–24 + Mitomycin 10 mg/m2 at day 2 during RT | 55 | 31% | N/A | 8.4 |
| Park et al. (69) | 2006 | 20 | 10 | 5-FU 500 mg/m2 for 3 days twice during RT with 2 weeks break | 56 | 37% | 14.6% | 10.4 |
| Chauffert et al. (70) | 2008 | 60 | 30 | 5-FU 300 mg/m2 5 days/week for 6 weeks + Cisplatin 20 mg/m2 5 days/week on weeks 1 and 5, maintenance Gem 1000 mg/m2 weekly | 59 | 32% | N/A | 8.6 |
| Crane et al. (71) | 2009 | 50.4 | 28 | Capecitabine 825 mg/m2 twice daily + Bevacizumab 5 mg/kg on days 1, 15, and 29; maintenance Gem 1000 mg/m2 weekly + Bevacizumab 5 mg/kg every 2 weeks | 82 | 47% | N/A | 11.9 |
| Sudo et al. (72) | 2011 | 50.4 | 28 | S-1 80 mg/m2 daily during and after RT | 34 | 70.6% | N/A | 16.8 |
| Oberic et al. (73) | 2011 | 54 | 30 | Docetaxel 20 mg/m2 weekly + 5-FU 200 mg/m2 daily during RT | 20 | 40% | N/A | 10 |
| Brunner et al. (74) | 2011 | 55.8 | 33 | 5-FU 1000 mg/m2 on days 1–5 and 29–33 + Mitomycin 10 mg/m2 on days 1–29 during RT | 35 | 40% | N/A | 9.7 |
| Huang et al. (57) | 2011 | 50.4–63 | 28–35 | 5-FU 200–300 mg/m2 5 days/week or 5-FU 500 mg/m2 on days 1–3 and 29–31 or capecitabine 1300–1600 mg/m2 daily during RT | 38 | 24% | N/A | 10.2 |
| Malik et al. (75) | 2012 | 50.4 | 28 | 5-FU based during RT* | 84 | 52.6% | N/A | 10.9 |
| Ikeda et al. (76) | 2012 | 50.4 | 28 | S-1 80 mg/m2 twice daily during RT, maintenance S-1 80 mg/m2 daily after RT | 60 | 72% | N/A | 16.2 |
| Schinchi et al. (77) | 2012 | 50 | 40 | S-1 80 mg/m2 twice daily during and after RT | 50 | 62% | 27% | 14.3 |
| Mukherjee et al. (58) | 2013 | 50.4 | 28 | Capecitabine 830 mg/m2 5 days/week induction and concurrent to RT | 36 | 79.2% | N/A | 13.4 |
| Herman et al. (78) | 2013 | 50.4 | 28 | 5-FU 200 mg/m2 daily during RT, maintenance Gem 1000 mg/m2 weekly | 90 | 36.7% | 10.3% | 10 |
| 5-FU 200 mg/m2 daily + TNFerade weekly during RT, maintenance Gem 1000 mg/m2 weekly | 187 | 41% | 11.3% | 10 | ||||
| Ducreaux et al. (79) | 2014 | 54 | 30 | Docetaxel 20 mg/m2 + Cisplatin 20 mg/m2 weekly during RT | 51 | 41% | 31% | 9.6 |
| Rembielak et al. (80) | 2014 | 50.4 | 28 | Cetuximab loading dose 400 mg/m2 + 250 mg/m2 weekly during RT | 21 | 33% | 11% | 7.5 |
| Kwak et al. (81) | 2014 | 50.4 | 28 | 5-FU 600–1000 mg/m2 during RT, maintenance Gem 200 mg/m2 weekly | 34 | 40% | 10% | 9 |
*Limited information about chemotherapy.